<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03172910</url>
  </required_header>
  <id_info>
    <org_study_id>PER977-02-012</org_study_id>
    <nct_id>NCT03172910</nct_id>
  </id_info>
  <brief_title>Study of Ciraparantag Administered to Volunteers Anticoagulated With Rivaroxaban, Measure Clotting Times Using WBCT</brief_title>
  <official_title>Phase 2 Placebo-Controlled, Single-Site, Single-Blind Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Perosphere, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Perosphere, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, single-blind, placebo-controlled study to assess the efficacy and
      safety of ciraparantag administered to healthy volunteers anticoagulated with rivaroxaban
      measuring clotting times using Whole Blood Clotting Time (WBCT).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 8, 2017</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy of ciraparantag in the reversal of anticoagulation</measure>
    <time_frame>4 days</time_frame>
    <description>To evaluate the efficacy of ciraparantag in the reversal of anticoagulation induced by rivaroxaban assessed by WBCT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>assess incidence of adverse events, (eg safety and tolerability of ciraparantag)</measure>
    <time_frame>10 days</time_frame>
    <description>asses vitals, incidence of AEs, assess blood chemistries</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1 Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administer ciraparantag or placebo dosing schedule 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administer ciraparantag or placebo dosing schedule 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administer ciraparantag or placebo dosing schedule 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administer ciraparantag or placebo dosing schedule 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administer ciraparantag or placebo dosing schedule 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administer ciraparantag or placebo dosing schedule 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciraparantag</intervention_name>
    <description>Reversal of rivaroxaban-induced anticoagulation via dose of ciraparantag or placebo</description>
    <arm_group_label>Cohort 1 Arm 1</arm_group_label>
    <arm_group_label>Cohort 2 Arm 1</arm_group_label>
    <arm_group_label>Cohort 3 Arm 1</arm_group_label>
    <arm_group_label>Cohort 1 Arm 2</arm_group_label>
    <arm_group_label>Cohort 2 Arm 2</arm_group_label>
    <arm_group_label>Cohort 3 Arm 2</arm_group_label>
    <other_name>PER977</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Reversal of rivaroxaban-induced anticoagulation via dose of ciraparantag or placebo</description>
    <arm_group_label>Cohort 1 Arm 1</arm_group_label>
    <arm_group_label>Cohort 2 Arm 1</arm_group_label>
    <arm_group_label>Cohort 3 Arm 1</arm_group_label>
    <arm_group_label>Cohort 1 Arm 2</arm_group_label>
    <arm_group_label>Cohort 2 Arm 2</arm_group_label>
    <arm_group_label>Cohort 3 Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria:

          1. Adults age 50 to 75 years

          2. Laboratory tests (chemistry, hematology and coagulation assessments) and urinalysis
             performed during screening up to 36 days prior to administration of study treatment
             deemed not clinically significant by the principal investigator.

          3. No clinically significant findings on 12-lead electrocardiogram (ECG) performed during
             screening

          4. Body mass index (BMI) 18 to â‰¤ 32 kg/m2, inclusive

          5. Male subjects agree to use appropriate contraception in addition to their partner
             using an acceptable form of contraception, when engaging in sexual activity during the
             course of the study. Moreover, male subjects should not donate sperm or attempt to
             impregnate a partner during the course of the study and for a period of 12 weeks
             following discharge from the study.

          6. Female subjects must have a negative urine pregnancy test at screening AND: be
             surgically sterile OR postmenopausal for the last three months, OR in a monogamous
             relation with a male partner who has undergone a documented vasectomy a minimum of 6
             months prior to study commencement. All females must agree to continue to use their
             method of birth control for the duration of the study and for a minimum of one
             complete menstrual cycle or 28 days following discharge from the study

          7. Subjects who have participated in a prior study of ciraparantag must have been
             discharged from the study a minimum of 1 month prior to the planned treatment.

          8. Subjects must understand and agree to comply with the requirements of the study and
             they must be willing to sign the informed consent form indicating voluntary consent to
             participate in the study prior to initiation of screening or study-related activities

        General Exclusion Criteria:

          1. History of major bleeding or clotting disorder

          2. Females with a history of dysfunctional uterine bleeding

          3. Smokers or use of tobacco and/or nicotine containing products within 3 months prior to
             dosing as determined by the subject's verbal history

          4. Pregnant or breast-feeding

          5. Males with a history of hormone therapy within 3 months prior to screening

          6. Taking any type of chronic medication (including vitamin, nutritional and herbal
             supplements) for more than 14 consecutive days within the 4 weeks prior to study entry
             (use of hormonal contraceptives is acceptable)

          7. Positive serologic test for human immunodeficiency virus (HIV), Hepatitis C virus
             antibody (HCV-Ab), or Hepatitis B surface antigen (HBsAg)

          8. Donation of blood or blood products within 56 days prior to screening

          9. Participation in any study with an investigational compound or device within 30 days
             prior to signing informed consent

         10. Active drug or alcohol dependence within the prior 12 months or any condition that, in
             the opinion of the Investigator, would interfere with adherence to study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Solomon S Steiner, PhD</last_name>
    <phone>(203) 885-1116</phone>
    <email>s.steiner@perosphere.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Barry H Ginsberg, MD, PhE</last_name>
    <phone>203-885-1111</phone>
    <email>b.ginsberg@perosphere.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Frontage Clinical Services Inc.</name>
      <address>
        <city>Secaucus</city>
        <state>New Jersey</state>
        <zip>07094</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander N. Prezioso, MD</last_name>
      <phone>201-416-7747</phone>
      <email>aprezioso@frontaglab.com</email>
    </contact>
    <investigator>
      <last_name>Alexander N Prezioso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2017</study_first_submitted>
  <study_first_submitted_qc>May 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2017</study_first_posted>
  <last_update_submitted>March 16, 2018</last_update_submitted>
  <last_update_submitted_qc>March 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PER977</keyword>
  <keyword>Ciraparantag</keyword>
  <keyword>Whole Blood Clotting Time (WBCT)</keyword>
  <keyword>Rivaroxaban</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

